LOGIN
Etanercept with methotrexate more effectively maintains low disease activity in RA
May 2013
Etanercept with methotrexate more effectively maintains low disease activity in RA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
To study the maintenance of low disease activity of rheumatoid arthritis, in first open label phase period of 36 weeks, all patients received 50 mg etanercept plus methotrexate every week. Those patients who had sustained low disease activity patients were then randomized to a double-blind period of 52 weeks into 3 groups: 50 mg etanercept plus methotrexate, 25 mg etanercept plus methotrexate, or ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.